Brief: Argenx Q4 Net Income USD -99.172 Million
29/02/2024 06:00
Feb 29 (Reuters) - Argenx Q4 total operating income USD 417.84 million. * Q4 operating expenses USD -556.464 million
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles